

Why Blood Glucose Monitoring Matters¹

- Diabetes affects 589 million adults globally.
- Approximately 81% of these individuals live in low- and middle-income countries.



- Glucose monitoring including self-monitoring of blood glucose (SMBG) and continuous glucose monitoring (CGM), is essential for effective diabetes management².

Key Challenges^{3,4}

Education gaps

Incorrect SMBG technique and limited DSME

Access gaps

High strip cost, limited device availability, and limited reimbursement

System gaps

Limited digital integration and limited policy support

The BiG Consensus – Expert Recommendations⁵

- Experts across Asia developed consensus based recommendations to improve BGM practices.
- Recommendation is based on a targeted literature review and structured focus areas include clinical decision making, patient engagement, technology use, and policy support.
- Emphasis on practical solutions for resource-constrained settings.


Recommended Monitoring Modalities in Real-World Settings

Diabetes Type	Preferred Monitoring	Resource-Constrained Settings
 Type 1 Diabetes	1. CGM 2. CGM + SMBG 3. SMBG	SMBG with intermittent CGM or SMBG only
 Type 2 Diabetes (Insulin)	1. CGM 2. CGM + SMBG 3. SMBG	SMBG with intermittent CGM
 Type 2 Diabetes (Non-insulin therapies)	1. SMBG 2. CGM	SMBG
 Gestational Diabetes Mellitus	SMBG + CGM	SMBG with intermittent CGM

- **Correct SMBG technique is essential; up to 30% of patients use incorrect methods.**
- **Encourage structured DSME.**

Step-by-Step SMBG

01



Wash hands with soap and water; dry thoroughly.

02



Lance the side of the fingertip using a sterile lancet.

03




Touch the test strip tip to the blood drop without squeezing.

04



Wait for the glucometer to display the reading.

05



Record the reading, time, and any relevant notes (e.g. meals, symptoms).

06



Safely dispose of used test strips and lancets in a sharp's container or sealed plastic bottle.

Technology & Innovation⁵

To improved adherence, SMBG device selection should prioritize:



Accuracy



Safety



Affordability



Ease of Use



Comfort



Availability

Supporting Safe and Effective Technology Adoption

- Strengthen patient education and trust
- Use approved devices
- Adopt hybrid SMBG + intermittent CGM models where appropriate



Policy & Reimbursement^{3,5}

Access to monitoring tools varies widely across countries.

To improve equity, policymakers may consider:

- Including BGM in national health packages
- Reducing device and strip costs through procurement
- Supporting DSME and HCP training
- Promoting culturally relevant education



CGM Reimbursement Status



SMBG Reimbursement Status



South Korea

Yes (70% for T1D)



South Korea

Yes (Varies)



Singapore

Subsidized (T1D)



Singapore

Yes (T1D/GDM under UCS)



Thailand

Yes (T1D)



Thailand

Yes (T1D/GDM under UCS)

No Reimbursement



India



Indonesia



Philippines



Malaysia

Largely Out-of-Pocket



India



Indonesia



Philippines



Malaysia

Way Forward: Actionable Steps

In daily practice:

- Implement structured SMBG and DSME during routine consultations.
- Use hybrid SMBG-CGM models for high-risk patients where resources allow.
- Reinforce proper SMBG technique: hand hygiene, site rotation, and safe lancet use.
- Encourage digital tools and apps for logging and sharing glucose data.

Advocacy Priorities:

- Support inclusion of SMBG in national health packages and public procurement to reduce strip costs. Additionally, set quality standards for devices and education to ensure safe and effective diabetes care.

Conclusion

SMBG remains central to diabetes care. Hybrid SMBG-CGM models optimise outcomes, especially with education and policy support. Regional collaboration is essential for equitable diabetes care.

FITTER BiG is sponsored by embecta

Chan SP et al. *Diabetes Ther.* 2026. doi:10.1007/s13300-026-01867-3

Access the full manuscript here:



BGM: Blood Glucose Monitoring; CGM: Continuous Glucose Monitoring; DSME: Diabetes Self-Management Education; HCP: Healthcare Professionals; GDM: Gestational Diabetes Mellitus; T1D: Type 1 Diabetes; T2D: Type 2 Diabetes; UCS: Universal Coverage Scheme

References: 1. International Diabetes Federation. Diabetes around the world - 2024. https://diabetesatlas.org/media/uploads/sites/3/2025/04/IDF_Atlas_11th_Edition_2025_Global-Factsheet.pdf. Accessed 4 Feb 2026. 2. National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management (NG17): economic model report. London: NICE; 2022. Available from: <https://www.nice.org.uk/guidance/ng28/evidence>. 3. Ewen M, Lepeska M, Abdramova A, et al. Availability, prices and affordability of self-monitoring blood glucose devices: surveys in six low-income and middle-income countries. *BMJ Public Health.* 2025. <https://doi.org/10.1136/bmjph-2024-001128>. 4. Aggarwal V. Globalizing continuous glucose monitoring systems: a paradigm shift from traditional self-monitoring blood glucose devices. *National High School Journal of Science (NHSJS).* 2025. Available from: <https://nhsjs.com/2025/globalizing-continuous-glucose-monitoring-systems-a-paradigm-shift-from-traditional-self-monitoring-blood-glucose-devices/>. 5. Chan SP, Tarigan TJE, Bansal B, et al. Blood Glucose Monitoring Expert Group and Best Practice Recommendation-FITTER BiG. *Diabetes Ther.* Published online May 5, 2026. doi:10.1007/s13300-026-01867-3 6. Le Floch JP, Bauduceau B, Lévy M, Mosnier-Pudar H, Sachon C, Kakou B. Self-Monitoring of Blood Glucose, Cutaneous Finger Injury, and Sensory Loss in Diabetic Patients. *Diabetes Care.* 2008;31(10):e73-e73. doi:10.2337/dc08-1174

Disclaimer: The information provided herein is for education and informational purposes only and should not be used to diagnose or treat any medical condition. For diagnosis or treatment of any medical condition please consult a qualified healthcare professional. Embecta Corp and/or its affiliates and employees are not liable for any damages or claims to any person in any manner based on this information.